新冠肺炎疫情下药品专利强制许可研究——以瑞德西韦为例  

Research on the Compulsory Licensing of Novel Coronavirus——Take Redcive as an Example

作　　者：张武军[1] 张博涵 Zhang Wujun;Zhang Bohan(School of Humanities and Social Science,University of Science and Technology, Beijing 100083,China)

机构地区：[1]北京科技大学文法学院,北京100083

出　　处：《科技进步与对策》2020年第20期83-88,共6页Science & Technology Progress and Policy

摘　　要：新型冠状病毒肺炎疫情暴发初期,瑞德西韦专利药品受到了广泛关注,虽然其仍在试验中,但给重症病患带来了希望。当前的疫情发展形势符合我国《专利法》规定的颁发专利强制许可的条件。首先概述药品专利强制许可及其特点,分析我国药品专利强制许可制度立法现状及存在的问题,借鉴国外药品专利强制许可制度立法实践,提出瑞德西韦药品专利强制许可应适当放宽申请主体限制、适度扩宽申请事由规定、善用药品专利强制许可制度谈判价格、制定符合国情的专利许可制度等建议,为我国启动药品强制许可制度提供政策依据。Since the early stage of the outbreak of the novel coronavirus,Remdeivir has receied extensive attentin,although it is still intrial,it brings a glimmer of hope to severe patients.Remdesivir is developed by Gilead company in the United States,and has made nearly perfect patent layout as early as in the research and development process.This paper first summarizes the compulsory license of drug patent and its characteristics,analyzes the current situation and existing problems of the compulsory license system of drug patent in China,draws lessons from the legislative practice of the compulsory license system of drug patent in foreign countries,proposes some suggestions,such as appropriately relax the restrictions of the applicant,appropriately expand the provisions of the application subject,make good use of the negotiation price of the compulsory license system of drug patent,and formulate the special license in line with the national conditions licensing system.

关 键 词：新冠肺炎 瑞德西韦 专利 交叉许可 强制许可 

分 类 号：D923.42[政治法律—民商法学]